Educational reference, not medical advice

This content is for general education only. It does not constitute medical advice, diagnosis, or treatment. Traditional uses described here are not clinically validated health claims under EU Regulation EC 1924/2006 and are not authorized by EFSA. Always consult a qualified healthcare provider before starting, stopping, or combining any supplement or medication. See our Terms and Impressum.

Herb–Drug InteractionsUpdated October 20269 min read

Echinacea and Medications: Documented Interactions

Echinacea is the supplement people often reach for during seasonal transitions, and modest research has been done on its effects. But the interaction profile is more complex than most people expect, especially for anyone with an autoimmune condition or anyone taking immunosuppressant medications.

The popularity is understandable. There is real science behind echinacea's effects on the immune system in laboratory studies, but clinical trials in colds have given mixed results. Echinacea also interacts with a number of medications, raises genuine questions for people with autoimmune conditions, and behaves differently depending on which species and plant part you are actually taking. This guide walks through what the research tells us, where the uncertainties lie, and what the EMA advises.

Key Takeaways

  • ✓Three species of echinacea are used medicinally (E. purpurea, E. angustifolia, and E. pallida), with different plant parts and active compound profiles. Not all echinacea products are interchangeable.
  • ✓Echinacea modulates the immune system by activating macrophages, increasing phagocytosis, and stimulating cytokine production, rather than simply “boosting” immunity in a general sense.
  • ✓Clinical research on echinacea's effects during seasonal transitions is modest and heterogeneous, with results varying substantially depending on the preparation used.
  • ✓The EMA monograph advises against echinacea in autoimmune disease, immunodeficiency and progressive systemic disorders, limits use to a maximum of 10 days, and does not recommend it for children under 12 or in pregnancy.
  • ✓Do not use if you are allergic to plants in the daisy family (Asteraceae); severe allergic reactions have been reported.
  • ✓The most clinically relevant drug interactions involve immunosuppressants, CYP3A4 substrates, and caffeine (via CYP1A2 inhibition), along with medications that carry a risk of liver toxicity.

1. What Echinacea Is

Echinacea is a genus of flowering plants in the daisy family (Asteraceae), native to eastern and central North America. The name comes from the Greek word echinos, meaning hedgehog, a reference to the spiny central cone of the flower. While the genus includes about ten species, three have been used extensively in herbal medicine and make up the vast majority of commercial products.

Echinacea purpurea is the most widely cultivated and studied species. It is a perennial with large, purple-pink daisy-like flowers, and it grows readily across a range of climates. In commercial preparations, both the aerial parts (stems, leaves, flowers) and the roots are used, though the aerial parts are more common in European products. E. purpurea is particularly rich in alkamides, chicoric acid, and polysaccharides, all of which contribute to its immunological effects.

Echinacea angustifolia has narrower leaves and was the species most used in traditional Native American medicine, particularly by the Plains tribes. The root is the primary part used.E. angustifolia contains high concentrations of echinacoside and alkamides, and it was the dominant species in North American herbal practice before E. purpurea gained commercial prominence due to its ease of cultivation.

Echinacea pallida (pale purple coneflower) has drooping, pale lavender petals. The root is the part used medicinally, and it has a distinct phytochemical profile from its relatives, being particularly rich in ketoalkenes and echinacoside but lower in alkamides. E. pallida root is the species recognized in the German Commission E monographs for supportive therapy of colds and urinary tract infections.

This distinction between species matters more than most consumers realize. A product labeled simply “echinacea” could contain any of these species, different plant parts, and wildly different concentrations of active compounds. The clinical research on one species and plant part does not automatically apply to another, which is one reason echinacea study results can seem contradictory.

2. How Echinacea Modulates Immunity

Macrophage Activation

One of the best-documented effects of echinacea is its ability to activate macrophages, the large white blood cells that serve as the immune system's first responders. Macrophages engulf and digest pathogens, dead cells, and foreign particles through a process called phagocytosis. Laboratory studies dating back to the 1980s, including work by Wagner and colleagues published inArzneimittelforschung, demonstrated that polysaccharides and alkamides from echinacea extracts significantly increased macrophage activity, both in cell culture and in animal models.

More recent research has clarified that alkamides, the lipophilic compounds that produce the characteristic tingling sensation on the tongue, are likely the primary drivers of macrophage stimulation. A 2005 study by Woelkart et al. in the Journal of Clinical Pharmacology showed that alkamides from E. angustifolia roots were rapidly absorbed after oral administration in humans.

Cytokine Production

Beyond macrophage activation, echinacea extracts influence the production of cytokines, the signaling molecules that coordinate the immune response. Research has shown that echinacea can increase the production of tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-10 (IL-10). Interestingly, some of these cytokines are pro-inflammatory (TNF-alpha, IL-1) while others are anti-inflammatory (IL-10), suggesting that echinacea's effect is more accurately described as immunomodulatory rather than simply stimulatory. The balance and timing of these cytokine effects likely depends on the dose, the specific preparation, and the state of the immune system at the time of exposure.

Enhanced Phagocytosis

Research in the Journal of Leukocyte Biology found that echinacea extracts enhanced the phagocytic activity of both macrophages and neutrophils, meaning these immune cells became more efficient at identifying and consuming pathogens. This effect was observed with bothE. purpurea and E. angustifolia preparations, though the magnitude of the effect varied between species and between root versus aerial part extracts.

3. The Cold and Flu Evidence

The Shah 2007 Lancet Meta-Analysis

One of the most influential reviews of echinacea for the common cold was the meta-analysis by Shah et al., published in The Lancet Infectious Diseases in 2007. This analysis pooled data from 14 randomized controlled trials and concluded that echinacea decreased the odds of developing a cold by 58% and reduced the duration of colds by 1.4 days. These are substantial effect sizes, and the publication in a top-tier medical journal gave the findings considerable visibility.

However, the meta-analysis was not without criticism. Some researchers pointed out that the included studies used a wide variety of echinacea preparations, species, dosages, and outcome measures, making the pooled analysis potentially misleading. The studies also varied in methodological quality, and critics argued that the strong summary result may not reflect the true effect of any single echinacea product.

The Karsch-Völk 2014 Cochrane Review

The Cochrane Collaboration, known for its rigorous systematic review methodology, published an updated review of echinacea for the common cold in 2014, led by Karsch-Völk et al. This review included 24 double-blind trials with over 4,600 participants. It found no clear benefit for treating colds; the authors could not rule out a weak benefit from some echinacea products. Prevention trials showed small, non-significant trends.

The Cochrane review's more cautious conclusion compared to Shah et al. reflects the challenge of pooling results across very different echinacea products. This is a situation where the details of what was actually in the capsule matter enormously. A well-characterized E. purpurea extract standardized to alkamides and chicoric acid is a fundamentally different product from a poorly standardized blend of unspecified echinacea species.

Summary of the Evidence

A Cochrane review found no clear benefit for treating colds; prevention trials showed small, non-significant trends. Other herbs like elderberry also have limited evidence in colds.

4. The Autoimmune Question

Perhaps the most important safety consideration with echinacea involves autoimmune conditions. This concern is not merely theoretical; it follows logically from echinacea's demonstrated mechanism of action. If echinacea activates macrophages, stimulates cytokine production, and enhances phagocytosis, these effects could be counterproductive in a body where the immune system is already attacking its own tissues.

Autoimmune diseases like systemic lupus erythematosus (lupus), rheumatoid arthritis, multiple sclerosis, and Crohn's disease are characterized by chronic, inappropriate immune activation. The inflammatory cascades that echinacea may promote are precisely the ones that drive tissue damage in these conditions. TNF-alpha, for instance, is so central to the pathology of rheumatoid arthritis and Crohn's disease that some of the most effective medications for these conditions (adalimumab, infliximab) work by blocking TNF-alpha specifically.

The European Medicines Agency (EMA) herbal monograph lists autoimmune diseases, immunodeficiencies, immunosuppression and progressive systemic disorders (such as tuberculosis, leukaemia, collagen diseases and multiple sclerosis) as reasons not to use echinacea. The German Commission E took the same position. No clinical trial has directly tested whether echinacea worsens autoimmune disease.

The EMA also lists hypersensitivity to plants in the daisy family (Asteraceae) as a contraindication. Do not use if you are allergic to plants in the daisy family (Asteraceae); severe allergic reactions have been reported.

If you have an autoimmune condition and are interested in immune support, there are other approaches that work differently in the body. This is a conversation worth having with a knowledgeable healthcare provider who understands both your condition and the herb's pharmacology.

5. Interactions With Immunosuppressants

Closely related to the autoimmune concern is the interaction between echinacea andimmunosuppressant medications. These drugs are prescribed to deliberately dampen immune system activity, and they include some of the most critical medications in transplant medicine and autoimmune disease management.

Cyclosporine and tacrolimus are calcineurin inhibitors used primarily to prevent organ rejection in transplant recipients. They work by blocking T-cell activation, a process that echinacea may promote. If echinacea stimulates the very immune pathways that cyclosporine is trying to suppress, the result could be reduced drug efficacy and an increased risk of organ rejection. For transplant patients, this is a potentially life-threatening scenario.

Corticosteroids like prednisone and methylprednisolone broadly suppress inflammatory and immune responses. They are used in autoimmune conditions, allergic reactions, and as part of transplant regimens. Echinacea's immune-stimulating effects could work at cross-purposes with corticosteroid therapy, potentially reducing the medication's effectiveness at controlling inflammation or immune overactivity.

Other immunosuppressants, including azathioprine, mycophenolate, and biologic agents like adalimumab and rituximab, operate through different specific mechanisms but share the fundamental goal of reducing immune activity. The Natural Medicines Comprehensive Database rates the echinacea-immunosuppressant interaction as “moderate” to “major” depending on the specific drug, and the combination is generally considered inadvisable without explicit guidance from your prescriber.

6. CYP Enzyme Effects

Echinacea's effects on the cytochrome P450 enzyme system are among the more complex and sometimes confusing aspects of its pharmacology. The CYP enzymes, particularly those in the liver, are responsible for metabolizing a large proportion of pharmaceutical drugs. When an herb inhibits a CYP enzyme, it can cause drug levels to rise (potentially increasing side effects). When an herb induces a CYP enzyme, it can cause drug levels to fall (potentially reducing effectiveness). St. John's Wort is the most dramatic example of the latter, but echinacea's CYP effects, while milder, still deserve attention.

CYP3A4: Conflicting Data

CYP3A4 is the single most important drug-metabolizing enzyme in the body, responsible for processing roughly 50% of all medications on the market. The data on echinacea's effect on CYP3A4 is genuinely conflicting. A 2004 pharmacokinetic (how the body processes a drug) study by Gorski et al. published inClinical Pharmacology and Therapeutics found that E. purpurea root extractinhibited intestinal CYP3A4 while simultaneously inducing hepatic CYP3A4. This seemingly paradoxical result means that echinacea could increase the bioavailability (how much your body actually absorbs) of some drugs (by reducing first-pass metabolism in the gut) while potentially increasing the clearance of others (by inducing liver metabolism).

A later study by Penzak et al. (2010) in Pharmacotherapy found that E. purpureainduced CYP3A activity but did not change exposure to lopinavir-ritonavir. For drugs with anarrow therapeutic index, meaning medications where small changes in blood levels can have serious consequences, even modest CYP3A4 modulation could matter. Medications in this category include certain anti-rejection drugs (cyclosporine, which adds a second layer to the transplant concern), some heart medications, and certain cancer chemotherapies.

7. The Caffeine Interaction

One of the more unexpected and practically relevant interactions involves echinacea andcaffeine. Caffeine is metabolized primarily by the enzyme CYP1A2 in the liver. The same Gorski et al. 2004 study found that E. purpurea root extract significantly inhibited CYP1A2 activity, reducing caffeine clearance by approximately 27%.

In practical terms, this means that taking echinacea alongside your usual coffee or tea intake could result in higher and more prolonged caffeine levels in your blood. For someone who drinks a moderate amount of coffee, this might manifest as increased jitteriness, difficulty sleeping, elevated heart rate, or anxiety. The effect is more pronounced in individuals who are already sensitive to caffeine or who consume large amounts.

It is worth being aware of, particularly if you notice that your usual coffee seems to hit harder after starting an echinacea supplement. The simple solution is to reduce caffeine intake slightly while taking echinacea, or to be mindful of caffeine timing relative to your echinacea dose.

The CYP1A2 inhibition also has implications for other medications metabolized by this enzyme, includingtheophylline (used for asthma), clozapine (an antipsychotic), andtizanidine (a muscle relaxant). For these medications, even a modest increase in blood levels could be clinically meaningful, and the combination warrants a conversation with your prescriber.

8. Liver Medication Interactions

Echinacea has been associated with rare cases of hepatotoxicity (liver damage). While these reports are uncommon and causality is difficult to establish definitively, a small number of case reports have described elevated liver enzymes or clinical hepatitis in individuals taking echinacea, sometimes in combination with other supplements or medications.

The practical implication is that combining echinacea with other medications known to carry a risk of liver toxicity may create an additive hepatotoxic burden. Medications in this category include acetaminophen (paracetamol) at high doses, methotrexate, certain statins, ketoconazole and other azole antifungals, andanabolic steroids. People with pre-existing liver conditions or those who consume alcohol regularly may be at higher risk.

If you are taking any medication that is known to affect the liver, or if you have a history of liver disease, it is worth discussing echinacea use with your healthcare provider.

9. Duration of Use

The EMA monograph limits use to a maximum of 10 days and does not recommend it for children under 12. Older sources, including the German Commission E, allowed longer courses; the EMA's more recent assessment is the stricter one. Long-term data are sparse, and the evidence does not support continuous or year-round use.

Pregnancy and breastfeeding: use is not recommended, because there are insufficient data.

If symptoms worsen, or a high fever develops, during use, the EMA advises consulting a doctor.

10. Species and Preparation Matter

If there is one message that runs through the echinacea research literature, it is thatthe details of the product matter enormously. Echinacea is not a single, uniform substance. The species, the plant part, the extraction method, and the standardization all influence what you are actually putting in your body.

When looking at an echinacea product label, here is what to pay attention to. First, thespecies should be clearly identified. Products that simply say “echinacea” without specifying the species are not providing adequate information. Most trials have studiedE. purpurea.

Second, the plant part should be stated. Aerial parts (above-ground portions) and roots have different chemical profiles and potentially different clinical effects. Many clinical trials in colds have used E. purpurea aerial parts or fresh-pressed juice. Root preparations have a different profile and are not necessarily interchangeable.

Third, look for standardization information. The best products will state standardization to specific marker compounds, most commonly alkamides, chicoric acid, or total phenolic content. Standardization helps ensure consistency between batches and provides a basis for comparing the product to what was used in clinical research.

Fourth, the form of extract matters. Fresh-pressed juice preparations (such as a fresh-pressed E. purpurea preparation used in several clinical trials) may have different bioavailability and effects compared to dried herb capsules, alcohol-based tinctures, or standardized dry extracts. The clinical evidence for one form does not automatically extend to another.

Finally, quality control and third-party testing are worth considering. A 2003 study by Gilroy et al. published in the Archives of Internal Medicine tested 59 commercial echinacea products and found that roughly 10% contained no measurable echinacea at all, while many others had significant discrepancies between label claims and actual content. Choosing third-party tested products can help reduce the risk of getting a substandard product.

Sources & Further Reading

  • Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. "Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis." Lancet Infect Dis. 2007;7(7):473-480.
  • Karsch-Völk M, Barrett B, Kiefer D, Bauer R, Ardjomand-Woelkart K, Linde K. "Echinacea for preventing and treating the common cold." Cochrane Database Syst Rev. 2014;(2):CD000530.
  • Gorski JC, Huang SM, Pinto A, et al. "The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo." Clin Pharmacol Ther. 2004;75(1):89-100.
  • Penzak SR, Robertson SM, Hunt JD, et al. "Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects." Pharmacotherapy. 2010;30(8):797-805.
  • Woelkart K, et al. "Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans." J Clin Pharmacol. 2005;45(6):683-689.
  • Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. "Echinacea and truth in labeling." Arch Intern Med. 2003;163(6):699-704.
  • Wagner H, Stuppner H, Schafer W, Zenk M. "Immunologically active polysaccharides of Echinacea purpurea cell cultures." Phytochemistry. 1988;27(1):119-126.
  • German Commission E. "Echinacea purpurea herba monograph." Bundesanzeiger. 1992.
  • European Medicines Agency (EMA). "Assessment report on Echinacea purpurea (L.) Moench, herba recens." EMA/HMPC/48704/2018.
  • European Medicines Agency (EMA), Committee on Herbal Medicinal Products. "European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens."
  • Natural Medicines Comprehensive Database. "Echinacea Monograph." Therapeutic Research Center.
  • National Center for Complementary and Integrative Health (NCCIH). "Echinacea." nccih.nih.gov.

This article synthesizes findings from peer-reviewed research, pharmacological databases, and clinical monographs. It is intended for educational purposes and does not constitute medical advice.

Check your specific combination

Enter your medications and any supplements you're considering into our free Interaction Reference.

Open Interaction Reference

Educational Disclaimer

The content on this page is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Traditional uses described here are not clinically validated health claims under EU Regulation EC 1924/2006 and are not authorized by EFSA. The information presented here does not replace a consultation with a qualified healthcare provider. Never start, stop, or change any medication or supplement regimen based solely on information found on this website. If you are experiencing a medical emergency, contact your local emergency services immediately. Individual results may vary, and what works for one person may not be appropriate for another.